Home 1 2 3 13 14

Me and My Money…a child’s story of diabetes

M&M Cover 300 small

Copyrighted in 2012, Me & My Money…a child’s story of diabetes, took two years to write…

From birthing thoughts, jotting ideas, typing a manuscript, carrying a daily journal, contacting an illustrator,  building the manuscript, proofreading and editing again and again and again and…you get the idea…this dream came to fruition.  It had do be done.  There is no other book like it — as far as my research goes — that reflects, mimics, or encourages diabetic children, T1Ds.  The book is now available to the general public in paperback form.  Celebrate!!

Submitting to a marketable world with a targeted audience, networking, promoting, speaking, through the main character, Kali with her dog, Money, brings attention to the increase of diabetes in animals – up 300% this past decade!

Through the wonderful insightfulness of illustrator Amy Pichly-Meyer who is responsible for the clarity of expression with the cover design, along with all 37 colored  illustrations, this book was built for you.  I am thankful for her friendship and abilities.

Briefly, the main character, Kali, is presently a fourth grader.  She was diagnosed with diabetes at the age of two.  Her rapid growth with blooming and wizened independence results from learning how to take care of herself.  Wayne, a best friend, knows her very well and together they embark on adventures through Wayne’s hobby, their separate and shared responsibilities, mutual friends, and more.  But Kali cannot forget her special pack!  She must carry this with her everyday, everywhere.

This book, along with the recent publication of Me & My Money Too…a child’s story with diabetes, are tools to understanding this disease.  Minute-by-minute self-care is introduced and forthcoming in this illustrated, easy-to-read chapter book, 104 pages long, appropriate for 8 years olds and available at Amazon.com in paperback edition as well as Kindle e-readers.   Local bookstores carry copies as well as local libraries with requests.  Please enjoy the following Chapter excerpts…

Chapter 1, Book One

Due to keeping up with my chores, I occasionally have some change in my pocket.  That’s because my parents give me a weekly allowance that I can spend when I want.

“Make sure you spend wisely,’ Dad says.  I’m not quite sure what “spend wisely” means, but I think I do okay with what I have.  For instance, one of my friends from school, Wayne, asked me to go to the hobby store one Saturday afternoon.  Because it is school summer vacation time, we could go almost any time, depending on our parents.  However, Saturday’s are best.

Wayne and I go way back, to kindergarten.  He is the only red-head kid in our whole grammar school, never mind our fourth grade.  He’s a full blown carrot top with thick hair in wavy curls.  This makes him real easy to spot in a crowd.  The girls in our class like Wayne more than the boys do.  I think this is because he has good manners and is polite.  It is either that or his clear sky blue eyes that sparkle.  Even his eyelashes are orange, matching his hair.  Most girls I know like blue eyes.  I never thought about it much.  My eyes are dark brown to match my light brown and blonde streaky hair.

Wayne is a pale looking kid.  Most of the time, the only color on Wayne’s face is because of his tannish-brown colored freckles.  I swear, if he didn’t have freckles, he would be white as a ghost!  I tease him about that, pretending that I can’t see him sometimes.  We laugh.  He blushes all red and pink.  It’s funny to see.  Wayne is shorter than I am — for now.  He teases me about my long brown hair — so flat, so straight and thin.  “There’s nothing to your hair,” he tells me as he quickly flicks it in the air.  “You don’t even have to brush it.  Your hair just hangs there off your fat head,” he often tells me as if I need to be reminded. 

I think Wayne is jealous of my straight hair.  Brushing his hair is a struggle because it is very thick.  Mine is a lot easier because it is stick straight.  He hates when his mother brushes his hair because “she always pulls it out of my head,” he told me one time.  “And you have a chubby little pug-nose.  Not like my pointy one at all,” he compares.  “But you get a tan in the summer.  I don’t tan, I burn.  It’s awful,” he explains.  That is true.

One summer that I remember, his mother covered his face and arms with white suntan lotion so  he wouldn’t get burned while playing with me in my back yard.  He looked so funny.  That stuff made him smell like the beach.  I laughed at him.  He didn’t like that.  And after a while, the suntan lotion disappeared.  But we stayed friends.  He wears that stuff all the time.  Sure, I use it too, but when I forget to rub it on my skin, I don’t get too worried.

“I guess you look like your father,” I told him because I think he does.  “I look like my mother,” I said.  And that’s okay with me because my mother is beautiful.  My Dad’s okay looking — for a Dad.  Sometimes he has a moustache.  Mom told him to shave it off because it made her sneeze when they kiss.  Eeeuu!  Sneezing and kissing, yuck!

“Kali,” my mom called up the stairs.  “Wayne is on the phone for you.”

“Okay.  Thanks.  I’ll get it up here,” I told her.

“Hi Wayne.  Wassup?”

“Hey.  Can you come to the train store with me today or what?  I’m looking for a certain model train engine and I think the Viking Hobby Store will have it.”

Well, I have no particular interest in model trains, so I knew I wouldn’t buy anything but I would go along with him anyway.  This is a wise decision.  After all, he is my very best friend.  Very best friends do things for each other whether we need to or like to or not.  It was Saturday morning anyway.  Cleaning my room could wait until I got back.  I was thinking, planning.

“Mom, Dad, is it okay with you if I go to the hoppy store with Wayne today?  He thinks he found the perfect train engine for his set.  He wants me to go and help him check it out.”

“I don’t mind.  Is your room picked up?” Mom asked.

“Not all the way yet, Mom,” I replied.  “I can finish when I get back.  All I have to do is fold my clothes and put them away.  A load of my socks and some t-shirts are still in the dryer.”

“Well, all right.  Did you ask your father?” Mom wanted to know.  “And don’t forget to take a snack and some juice boxes with you.”

“I know.  I already have a pack of peanut butter nabs in my sack with some water.  I don’t know where Dad is.  I thought he was in the kitchen with you.  Maybe he’s in the garage.”

“Okay,” continued my mother.  “If you don’t see your father on your way out, I’ll tell him.  If you do, please remind him that we’re going shopping today.  Oh, are you and Wayne taking your bikes or walking?”

“I think we’ll walk.”  And out the back door I went.

Chapter 2

Wayne lives four houses away from me.  I took the short-cut over to his house through a wildflower field.  I often come here to pick my mother some flowers.  I like to pick flowers for her.  There are all kinds of wildflowers in this field: yellow ones, pink ones, purple ones with yellow centers.  I don’t know the names of these flowers, I just know they are pretty and Mom likes them.

After I met Wayne on the front porch of his house, we proceeded to walk to this particular ‘train store’ as he calls it.  It is really a hobby store that has lots of other things of interest besides trains.  I’ve been in there with one of my older cousins.  She was looking for some particular, special types of paint brushes made with camel’s hair.  I thought that was cool — paint brushes made out of a camel’s hair!  There are small glider planes in this store with hand-held motor devices; there are different kinds of wood burners and wood carving tools; there are even lots of different colored rubber fish bait things — lures.  I liked those because they are shiny, squishy, and they squiggle.  Things that would attract a fish — go figure!  Wayne had been going on about a certain model train engine he saw in here a while ago.  It took him weeks and weeks to save up his allowance money to buy it.

“Hey, before we walk too far, is your insulin pump filled up?” Wayne asked.  “I hope it doesn’t beep like crazy while we are out.  I would hate to have to leave early so you could fix it.”

“Yes, it’s fine.  I filled it up with insulin yesterday morning and changed the needle site.  We are good to go!”  I planned this on purpose.  I knew he would ask.  I am diabetic.  Wayne knows.  Among many other things, I do take care of myself and my diabetes.  I have to test my blood sugar levels many times each day.  Diabetes is a disease that causes me not to digest food properly.  Because of that, I wear an insulin pump.  I used to have to take insulin shots before I got the pump.  Having the pump is much easier.  An insulin pump squirts insulin into my body, automatically, a tiny bit at a time.  A “squirt” is maybe the size of a pencil tip or the size of a period at the end of a sentence.  My parents had to give me insulin shots before I learned to give them myself.  I still keep syringes handy, in case the pump breaks down for whatever reason.  This is called having “Plan B” which is important. 

Read more of Kali’s young life with diabetes in “Me & My Money…a child’s story of diabetes.”  Available at Amazon.com.

New News! JDRF 2017…continued T1D Research and Encouragement. Go Team!!

Blog

Northern California Inland Chapter
MENU
Northern California Inland Chapter

×

JDRF One Walk Sunday October 1st

June 27, 2017

2016 One Walk JDRF will be hosting its annual One Walk on Sunday October 1, 2017 at the State Capitol in Sacramento.…
Read more

Meet the Board President

June 27, 2017

Board President Aaron Gurley Aaron Gurley, General Manager for Premier Pools and Spas, was recently appointed Board President of the Northern California…
Read more

Have FUN while giving back at California’s Great America!

June 22, 2017

Life with type 1 diabetes (T1D) can come with a lot of “roller coasters” – the blood glucose kind, the emotional kind, and…
Read more

2017 Children’s Congress Delegate, Vincent Po’oi

June 22, 2017

This July, 13 year old Vincent Po’oi of Sacramento will be joining over 150 children, ages 4-17, from around the United States…
Read more

Thank You For A Memorable One Party Gala!

May 17, 2017

On April 22  in the historic Memorial Auditorium in Downtown Sacramento more than 300 people gathered to recognize advances in the fight against type…
Read more

JDRF General Research Progress Report for 2014-2015

December 19, 2014

It has often been said that the road to progress is rarely a straight line. At JDRF, we know nothing holds truer…
Read more

Walk Day Is Almost Here!

September 25, 2014

My T1D Life Blog-The Personalization Station!

August 7, 2014

Personalization is the key to setting your walk page apart from the rest. This allows you and your teammates the ability to…
Read more

Book Marketing

Continuing my ‘book marketing procedures,’ I am once again engaged in coordinating numerous “Authors Showcases” at local Sacramento County, California libraries.  Promotion of my four award-winning books (www.mydiabeticsoul.com) is acceptable in such a free, and public venue.  Encouragement and attention increases in such a familiar setting with numerous author participants and the general public visitors.  Libraries are happy places.

As a ‘free-agent,’ sole-proprietor, self-published author, distribution and supply of my books is up to me and only me.  When I began this trek in 2010, it was new to me, a bit frightening, unfamiliar.  Thanks to my Masters Degree program (University of Pheonix, 1999), I gained the confidence required with public speaking.  Thanks to a personal friend, also a self-published author, for leading me to my first writers meeting and club, I joined and became not only acquainted with other writers, published and unpublished, but my yearly membership lasted nine years leading me to marketing and promotional venues for all its members.

I like to think I help the general public become aware of my books (subject matter is T1D – Type One Diabetes) and their subject matter, the cost of each book and where to find them.  Along the way, many other authors are consistently invited to participate to do the same.  This process of multiple participant invitations continues to be more comfortable for me, having another person, specifically and author or two, to share in these experiences.  It’s happy work.

For instance, an upcoming “Authors Showcase” with twenty authors is taking place at the Carmichael, California Library on Saturday, August 5, 2017, between 1 & 4pm.  Other such events are in the works as well.  Twenty individual authors, coming together in one place, most having the same dream as I – to promote out works, speak to individuals about out artistic values and beliefs – the whos, whats, whens, wheres, hows, and how muches involved in such a career.  After all, writing is an individual personal art.

Libraries are free, comfortable, accommodating, safe, and easily accessible.
Other book marketing venues – with or without a price tag – have been city and country fairs with or without my supplying a personal E-Z up (tent); private speaking engagements in Church (Holy House) basements; and Assisted/Independent Living Centers where the residents are absolutely thrilled to listen about my books.  All it takes is a little time for  research location of resources, a hone call, and your in!

My next marketing venture is to gather individual writers from separate groups/clubs to join in an event.  With numerous writing groups and clubs in this area, I wouldn’t think the opportunity would be too difficult.  There is the beloved NCPA (Northern California Publishers and Authors Organization) CAW (California Writers), GCW (Gold Country Writers), SSWC (Sacramento Suburban Writers Club), SIC (Sisters In Crime), and others.  This twinkling idea will grow – that’s how I work, with my brain.  Heck, it’s appealing to me, encouraging, insightful, happy, especially when others are involved.

Just sayin’…

A. K. Buckroth

NEWS: From The Juvenile Diabetes Research Foundation

Cell Conversion Could Be a Change for the Better

Can the loss of functional beta cell mass in T1D be reversed to restore insulin production? That is a fundamental question for those working to eliminate the disease; and JDRF is supporting research that could provide some answers.

Unlike some other cells in our bodies, insulin-producing beta cells don’t replicate readily, especially as we age. That’s a problem for researchers who are working to cure T1D by rebuilding functional beta cell mass lost to autoimmune attacks. But some investigators have noticed that, with the right encouragement, other islet cells can change identity and take on the characteristics of beta cells, including insulin production. JDRF is supporting several projects seeking to exploit that ability, hoping to regenerate beta cell mass. Two JDRF-funded investigators recently announced they’d found ways to chemically stimulate pancreatic alpha cells—the cells that normally produce glucagon—to change into insulin-producing beta-like cells. French researcher Patrick Collombat, Ph.D., found that GABA, a naturally occurring chemical and common dietary supplement, triggers the conversion of mouse alpha cells into beta-like cells. Treating diabetic mice with GABA fully restored beta cell mass and reversed their diabetes, and human islets transplanted into mice appeared to respond in the same way as the mouse islets. Investigator Stefan Kubicek, Ph.D., at the Austrian Academy of Sciences realized similar results using a type of FDA-approved anti-malarial drugs called artemisinins. These results suggest it may be possible to “retrain” alpha cells that continue to survive in the pancreas of a person with T1D into insulin-producing cells, a critical step toward a cure.

Next steps for both investigators include working to better understand the processes and mechanisms underlying the alpha-to-beta cell changes, which could help identify improved compounds that are able to trigger the same alterations. Continued research could also enable them to determine how best to use these compounds to treat the disease. They’ll also investigate whether the changed cells can reliably reverse mouse models of T1D. Most importantly, these compounds, which are already in use in humans, may be moved quickly into clinical testing for the treatment of T1D. Restoring functional beta cell mass and renewing the body’s ability to produce insulin is a high priority for JDRF because it would reduce or eliminate the daily burdens and hazards of managing blood-glucose levels. Even partial restoration or maintenance of beta cell function could offer significant benefits to people with T1D, including slowing or preventing progression of the disease, reduced insulin requirements, improved glucose control and a lower risk of complications. Find out more about JDRF’s Beta Cell Restoration Program at jdrf.org.

Why is this important?

Restoring the body’s ability to produce insulin will enable people with T1D to more easily manage their blood-glucose levels and may ultimately provide a cure for the disease. To do that, it’s necessary to have a sufficient number of functional beta cells, whether they’re naturally produced, chemically transformed or implanted. Once we find ways to restore and protect functional beta cell mass, the burdens, limitations and fears associated with T1D become things of the past.

By Eileen Crowley • JDRF

READ THIS! “Making Insulin Affordable” By Fran Quigley

About the Author:

“Mbolonzi Mbaluka understands. A Kenyan living with type 1 diabetes, he has had to skip insulin injections, sometimes because he could not afford the cost and sometimes because local hospitals ran out of stock. A fellow Kenyan patient recently died after going two months without insulin, which in many countries can cost up to 50 percent or more of the average income. For example, in Brazil, insulin and supplies can cost over 80 percent of an average income. “The insulin and the equipment together are just not affordable for many,” Mbaluka says.

“Insulin is a pancreas-created hormone that allows the body to absorb and deploy sugar from consumed food. For people with type 2 diabetes, the pancreas struggles to keep up with the body’s insulin demand, either because the pancreas is not producing enough or because the body has developed insulin resistance. For persons with type 1 diabetes, their body’s immune system has damaged or destroyed the insulin-producing cells in the pancreas. A lack of insulin causes blood sugar levels to rise, damaging the heart, kidneys, eyes, and nerves. Over 400 million people globally have diabetes. Lack of widespread testing makes it hard to apportion the percentages between type 1 and type 2, but the majority of those people have type 2 diabetes. And according to some estimates, half of those who need insulin cannot reliably get access to it.  People with type 2 diabetes often need to take insulin shots on a temporary or permanent basis. For people with type 1 diabetes, the equation is much more uniform, and more stark: they must inject insulin in order to stay alive.

“The discovery of insulin in the 1920s by a University of Toronto research team is one of history’s great pharmaceutical success stories. Orthopedic surgeon Frederick Banting and medical student Charles Best were able to extract insulin from an animal pancreas and inject it into a diabetic human, a groundbreaking advancement that earned Banting the Nobel Prize. Suddenly, a fatal disease became a survivable, chronic condition—as long as the insulin was available to the patient.

“The researchers were ideologically opposed to monopoly patenting of biomedical discoveries, but they were eager to see that wide distribution begin as soon as possible. And so, the researchers took out a patent for insulin, which they promptly sold to the university for $1 each. The plan was for the university to partner with pharmaceutical companies that were prepared to mass produce and distribute insulin. (A few decades later, Jonas Salk would famously refuse to patent the polio vaccine.)

“The researchers who discovered insulin were ideologically opposed to monopoly patenting of biomedical discoveries.

“For a while, the plan worked. Insulin became widely available and affordably priced. It was even improved upon. Innovations reduced the frequency of needed injections. Soon, the first human insulin and then synthetic insulin, known as analogues, replaced the original animal-extracted version. Yet those changes also caused problems. Each improvement allowed for corporations to take out their own patents on the new versions, and the price began to increase. The far-cheaper former versions of insulin, which experts generally agree were not significantly less effective than the enhanced iterations, disappeared from the market.

“Although the changes in insulin over the years have brought some benefits to patients, some experts say that the insulin producers’ tactics have corrupted the original public health vision of the medicine’s inventors. “I don’t think it takes a cynic such as myself to see most of these (insulin) drugs are being developed to preserve patent protection,” Harvard Medical School professor David Nathan told The Washington Post. “The truth is they are marginally different, and the clinical benefits of them over the older drugs are zero.”

“Yet the three main manufacturers of insulin—Eli Lilly, Sanofi Aventis, and Novo Nordisk—have dramatically raised prices on the newest versions. A 2016 study published in the Journal of the American Medical Association showed that the cost of insulin in the U.S. almost tripled between 2002 and 2013, and prices have continued to climb since. A U.S. patient’s out-of-pocket cost for a month’s supply of Eli Lilly’s Humalog can be over $400.

“For the drug companies, insulin is a hugely profitable product. Although manufacturers keep the cost of insulin production a tightly-guarded secret, U.S. prices are likely hundreds of times higher than the expense of making the drug. With annual revenues of $31 billion and growing, insulin is one of the highest-grossing medicines in the global market.

“But for patients who are dependent on insulin, its cost is creating a crisis—and not just in low-income countries but also in the comparatively wealthy United States. Increasingly, a lack of insurance coverage for the medicine or high-deductible coverage leaves people with diabetes paying as much as half their income for insulin. Patients report skipping doses, injecting expired insulin, and even starving themselves to control their blood sugar. Some patients are intentionally allowing themselves to slip into the life-threatening state of diabetic ketoacidosis just so they can obtain free insulin samples from emergency rooms. Not surprisingly, physicians report seeing more patients in distress because they can’t afford their insulin.

“Americans with type 1 diabetes are particularly anxious over the likely repeal of the Affordable Care Act, which protects them against coverage denials because of pre-existing conditions and against lifetime caps on coverage. Amy Leyendecker, who lives in Elizabethtown, Kentucky, currently has most of her insulin and equipment costs paid by insurance provided by her husband’s employer. But she has been without health insurance before, and is anxious about what may happen when her husband retires in a post-ACA world. “I have a five-month stash of insulin in my refrigerator that a friend brought in from outside the U.S.,” she says. “This is life-and-death for me.”

“THE PUSH FOR LOWER PRICING”

“Among those fighting for more affordable insulin is T1International. Elliott and Mbolonzi Mbaluka are active members. The group’s founder and director, Elizabeth Rowley, began the organization as a blog, but she quickly discovered that there was a global population of persons living with type 1diabetes eager to connect—and to speak out. One core purpose of the group is to provide a forum for those patient voices. “There are a lot of difficult challenges people with type 1 struggle with,” Rowley says. “And number one among those is that the prices for insulin and equipment are just far too high.”

“Rowley and her colleagues try to channel widespread frustration into focused activism. T1International’s detailed toolkit for advocacy includes global case studies of successful campaigns for better insulin access, tactical guidance, and tips on dealing with elected officials—“Sometimes you have to make the politician think it was their idea.” They collect data on insulin and supply costs, publish accounts of patient experiences worldwide, and even steer U.S. patients toward the attorneys who have filed a class action suit against the insulin manufacturers. That lawsuit, in the U.S. District Court in Massachusetts, alleges price collusion among the three major manufacturers, citing years of remarkably similar price increases by Eli Lilly, Sanofi, and Novo Nordisk.

“T1Inernational’s support of that litigation, and its outspoken criticism of insulin pricing, put it squarely at odds with the pharmaceutical industry. That also makes the group different from most patient advocacy groups. Groups including cancer patient groups and allergy and asthma patient groups have come under criticism for not speaking out in response to drug pricing issues. Most even declined to weigh in even during the recent high-profile Epi-Pen and Martin Shkreli “pharma bro” debates, in which triple-digit drug price increases led to public outcry and Congressional hearings.

“In fact, patient groups often vigorously support the pharma industry agenda, while at the same time receiving significant pharma funding. A 2016 report by the U.S. advocacy group Public Citizen revealed that at least three-quarters of the patient groups who actively opposed an Obama administration proposal to reduce Medicare drug expenditures received pharma industry donations. Another study showed that over 90 percent of patient groups participating in a discussion of FDA drug approval reform were pharma-funded.  Most patient groups that opposed California’s 2016 ballot measure to regulate the medicine prices paid by state government proved to be heavily funded by pharmaceutical corporations.

“Not surprisingly, access to medicines advocates report that patient group representatives privately admit that they won’t speak out on drug pricing for fear of losing state funding. That fear is well-founded. The U.S. National Multiple Sclerosis Society endured push-back from its pharma funders when it dared to mention concerns over the cost of multiple sclerosis drugs that average $78,000 annually, a 400 percent increase in little over a decade.

“Patient group representatives privately admit that they won’t speak out on drug pricing for fear of losing state funding.

“For patient groups, the pharma industry is the best source both for operational funding and the drug donations that can be shared with desperate patients. So most groups choose to accept the funding and devote themselves to patient education and direct aid, muting any criticism. T1International made the choice to favor advocacy, but it was not an easy one. Elliott recalls an early board meeting where he argued for a focus on patient service mission instead. “I am glad I was outvoted,” he says now. “T1I fills a much-needed need in the diabetes patient community.”

“T1International refuses on principle to accept pharma industry donations. “Even if they don’t force you to take certain positions, it is human nature not to want to bite the hand that feeds you,” Rowley says. But that choice has implications. Although pharma-funded organizations such as the International Diabetes Federation and the American Diabetes Association are well-staffed, T1International gets by with an all-volunteer workforce, anchored by Rowley’s 40-plus hours of unpaid labor each week.

“She and other volunteers continue to spend those hours ratcheting up the pressure on lawmakers and companies to address insulin pricing. They push for congressional hearings on the alleged industry collusion, expose the limitations of well-publicized corporate drug donation programs, and build a social media community around the theme of #insulin4all. And they are giving voice to the argument that essential medicines should be once again a public good, not a for-profit commodity. “It is a tragedy that a drug like insulin, invented by people who were motivated by a goal of access to all, is so clearly unavailable to so many,” Elliott says. “People are dying, and that is a status quo no one can defend.” “

The Sixteen Types…(of personality traits)

…from “Please Understand Me” by Keirsey & Bates

  1.  “Extroverted INtuitive Feeling Judging, known as “ENFJs,” are outstanding leaders of groups and growth groups.  They have the charming characteristic of seeming to take for granted that they will be followed, never doubting that people will want to do what they suggest.  And, more often than not, people do, because this type has unusual charisma.  ENFJs place a high value on cooperation from others and are most willing to cooperate themselves.”
  2. INFJs focus on possibilities, think in terms of values and come easily to decisions.  The small number of this type (1%) is regrettable, since INFJs have an unusually strong drive to contribute to the welfare of others and genuinely enjoy helping their fellow men [or women].  This type has great depth of personality; they are themselves complicated, and can understand and deal with complex issues and people.”  https://www.verywell.com/infj-introverted-intuitive-feeling-judging-2795978
  3. “For ENFPs (https://en.wikipedia.org/wiki/ENFP), nothing occurs which does not have some significance, and they have an uncanny sense of the motivations of others.  This gives them a talent for seeing life as an exciting drama, pregnant with possibilities for both good and evil.  This [personality] type is found in only about 5% of the general population, but they have great influence because of their extraordinary impact on others.”
  4. “INFPs (https://www.verywell.com/infp-a-profile-of-the-idealist-personality-type) represent a calm, pleasant face to the world and are seen as reticent and even shy.  Although they demonstrate a cool reserve toward others, inside they are anything but distant.  They have a capacity for caring which is not always found in other types.  They care deeply–indeed, passionately– about a few special persons or a cause. One word that captures this type in idealistic.  At times, this characteristic leaves them feeling isolated, especially sin INFPs are found in only 1% of the general population.”
  5. “If one word were used to capture ENTJs style, it would be commandant (https://en.wikipedia.org/wiki/ENTJ).  The basic driving force and need of ENTJs is to lead, and from an early age they can be observed taking over groups.  This type is found in approximately 5% of the total population.  They have a strong urge to give structure wherever they hare–to harness people to distant goals.”
  6. “INTJs are the most self-confident of all they types, having “self-power” awareness.  Found in about 1% of the general population, the INTJs live in an introspective reality, focusing on possibilities, using thinking in the form of empirical logic, and preferring that events and people serve some positive use.”  (https://www.verywell.com/intj-introverted-intuitive-thinking-judging-2795988)
  7. ENTPs wish to exercise their ingenuity in the world of people and things.  Found in about five out of every hundred people, ENTPs extravert intuition; thus they deal imaginatively with social relationships as well as physical and mechanical relations.  They are very alert to what is apt to occur next, and always sensitive to possibilities.”  (https://www.verywell.com/intj-introverted-intuitive-thinking-judging-2795988.)
  8. INTPs exhibit the greatest precision in thought and language of all the types; they tend to see distinctions and inconsistencies in thought and language instantaneously.  The one work which captures the unique style of INTPs is architect–the architect of ideas and systems as well as the architect of edifices.  This type is found in only 1% of the population and therefore is not encountered as frequently as some of the other types.”  (https://en.wikipedia.org/wiki/INTP.)
  9. ESTJs are very much in touch with the external environment.  They know their community and usually are pillars of strength.  The best adjective to describe ESTJs would be responsible.  The represent about 13% of the general population.”  (https://www.16personalities.com/estj-personality.)
  10. ISTJs are characterized by decisiveness in practical affairs, are the guardians of time-honored institutions, and, if only one adjective could be selected, dependable would best describe this type which represents about 6percen of the general population.”  (http://www.personalitypage.com/ISTJ.html.)
  11. ESFJs, the most sociable of all types, are energized by interactions with people, tending to idealize whatever of whoever they admire.  Harmony is a key to this type, which is represented in about 13 percent of the general population.”  (http://www.truity.com/personality-type/esfj.)
  12. “Six out of every one hundred people are ISFJs.  Here the primary desire is to be of service and to minister to individual needs.  ISFJs carry a sense of history, a sense of continuity with past events and relationships.  Traditions and the conservation of resources are valued highly.  …ISFJs believe work is good, play must be earned.”  (http://www.personalitypage.com/ISFJ.html.)
  13. ESTPs are men and women of action.  When someone of this personality is present, things begin to happen.  The lights come on, the music plays, the game begins.  And a game it is for the ESTP, the outstanding entrepreneur, the international diplomat, the conciliator, and the negotiator par excellence.  Approximately 13% of the general population are of this extraverted, sensing, thinking, perceiving type, and if only one adjective could be used to describe ESTPs resourceful would be an apt choice.”  (https://www.16personalities.com/estp-personality.)
  14. ESFPs radiate attractive warmth and optimism.  Smooth, witty, charming, clever, voluble, and open to the environment–this describes ESFPs who, like ESTPs, represent about 13% of the general population.  They are great fun to be with and are the most generous of all the types.  Performer would be the word which best describes an ESFP.”  (https://www.verywell.com/esfp-extraverted-sensing-feeling-perceiving-2795984.)
  15. “Just as impulsive as other SPs, the ISTP’s life is artful action–and action is end in itself.  Action for the ISTP is more gratifying if it is born of impulse rather than of purpose.  If the action is in the service of an end or aim, let the aim look out for itself; it cannot be allowed to influence execution.  The act is self-directed, self-leading, containing its own imperatives which are egalitarian an can be fiercely loyal to “brothers,” but they can also be fiercely insubordinate, seeing hierarchy and authority as unnecessary and even superfluous.’  (https://www.verywell.com/istp-introverted-sensing-thinking-perceiving-2795993.)
  16. Although all SPs (Sensuous Performers) are artisans in their nature, they usually do not pursue their artistry with the same devotion to grace and adornment as the ISFP.  For whatever reason, the ISFP seems more inclined to the “fine arts” than the other SPs; so when an especially gifted composer, painter, or dance shows up, he or she, more frequently than not, possesses the character of the ISFP.  Beethoven, Toscanini, Rembrandt, and Nijinski, as shown by typohistorical research, were clear-cut ISFPs.  But the ISFP temperament is very difficult to observe, even in the great artists, and so ISFP is probably the most misunderstood of all the types.”  (https://www.16personalities.com/isfp-personality.)

From A. K. Buckroth, it’s fun to know, it’s fun to learn!  I hope you enjoyed reading this book excerpt.  I enjoyed sharing it with my readers.  Just sayin’….  #buckroth

Artificial Pancreas for T1Ds

JDRF Celebrates Historic Artificial Pancreas Success Bringing Life-changing Benefits to People with Type 1 Diabetes

FDA Approves Medtronic Hybrid Closed Loop System

“On September 28, 2016, the type 1 diabetes (T1D) community reached a major breakthrough with the FDA’s approval of the Medtronic hybrid closed loop system. The system is the first ever approved to automate the dosing of insulin to reduce high blood sugar levels.

“The new Medtronic MiniMed 670G artificial pancreas system is a life-changing breakthrough that allows people with T1D to stay closer to their target blood sugar levels more consistently. JDRF celebrates a decade of dedicated partnership, collaboration, funding and advocacy that have made it possible to reach this landmark goal.

Today’s announcement is a historical achievement for JDRF and the entire T1D community. After years of laying the ground work, this life-changing breakthrough is a true testament to the reason JDRF exists, which is to accelerate ways to cure, prevent and treat this disease,” said Derek Rapp, JDRF President and CEO.

“The artificial pancreas system is designed to use Medtronic’s MiniMed 670G insulin pump, 4th-generation sensors and a control algorithm to automate basal insulin delivery to maximize the time glucose levels are in a healthy range throughout the day and night. The system is fully integrated between the pump and sensor, with no need for a separate smartphone or CGM monitor. The AP system will give many people with T1D new freedom and peace of mind as for the first time, they may be able to sleep through the night without periodically waking up to check and manage their blood glucose levels.

“A study recently published in the Journal of the American Medical Association (JAMA) found that on the 670G system, 124 patients had no episodes of severe hypoglycemia or ketoacidosis over 12,389 patient days.

“Further, the 670G system kept people with T1D within their desired blood sugar range 73.4% of the time, vs. 67.8% without the system. At night, the most dangerous time for blood sugar highs and lows, the difference was even more pronounced, 76.4% in range vs. 67.8% without the system.

“Les Hazelton, who participated in one 670G trial, explains, “Bottom line: I feel better today and since going into this study, than at any point after I was diagnosed — physically, emotionally, confident in how I’m managing my diabetes. You can get emotional about it. On the good days, if there are enough of them, you recall how you feel — that’s how I feel almost every day now. That’s what it has done to help me.”

“JDRF has been pivotal in developing and pursuing its Artificial Pancreas Project since 2006. In less than 10 years, JDRF transformed the AP field, working closely with numerous partners, researchers and companies to overcome the challenges that prevented AP technology from moving forward. Together, JDRF, the Helmsley Charitable Trust, and the National Institutes of Health’s Special Diabetes Program have funded hundreds of millions of dollars in research across the globe to develop and test sophisticated computer algorithms and components needed for the AP systems. JDRF developed a roadmap to create successively advanced versions of the AP, which has been embraced by manufacturers to guide their own R&D programs. JDRF has also worked with the leadership of the Senate and House Diabetes Caucus and other allies in Congress to provide research funding through the Special Diabetes Program and overcome obstacles that could delay delivery of AP systems to people with T1D.

“JDRF funded early artificial pancreas research as part of its hypoglycemia prevention efforts, and in 2006, JDRF launched the Artificial Pancreas Consortium, made up of leading endocrinologists, mathematicians, and engineers at top research institutions in the U.S. and Europe. JDRF and the FDA partnered to proactively address regulatory obstacles, leading to the 2012 FDA guidance for artificial pancreas device systems, which provided a regulatory pathway for system commercialization.

“This month’s huge leap forward would not have been possible without the support of JDRF’s many partners, notably, the Helmsley Charitable Trust, and everyone in the T1D community who has contributed their time, energy and financial support over the last decade.

“But while this is a breakthrough, it is not the end goal. JDRF remains committed to the search for a cure and to ensure people are healthier and have a reduced diabetes management burden until we get there.

“This is a fantastic step forward, but we are not done, JDRF will continue supporting other artificial pancreas advancements and advocating for broad access to this life-changing technology,” said JDRF Chief Mission Officer Aaron J. Kowalski, PhD. “Next generation systems are in the pipeline that could provide even better outcomes with less burden. And our work will not be finished until we cure and prevent T1D.

“More than 10 years of hard work have brought us to this point. In the past decade, JDRF has invested more than $116 million in diverse artificial pancreas research projects, with the goal of aiding the development of multiple, reliable treatment choices for people living with T1D. With continued collaboration and support, imagine what we can accomplish next!”

#buckroth

Why Sugar-Free Foods Have a ‘Laxative Effect’

…by Kristen McNutt, Phd., JD.

“Like fiber, sugar replacers are only slightly digested – or not at all. Therefore, the most low-digestible carbohydrate that is eaten is not absorbed. The body’s normal response to unabsorbed carbohydrates is simply to dilute them by pulling water across the intestine lining into the upper part of the intestine. When low-digestible carbohydrates move into the large intestine, most of that water moves back in the opposite direction. Depending on how much water flowed in and out, stools might be unchanged, soft or loose. This is why low-digestible carbohydrates are sometimes used to relieve constipation.

“Some bacteria that live in the large intestine can “eat” low digestible carbohydrates, and they use this type of carbohydrate for their own growth. After they have eaten, gases and short fatty acids remain. That’s why beans, fiber and other sources of low-digestible carbohydrates may cause an increase of gas. Recent research shows that some of the short fatty acids promote intestinal health. Furthermore, low sugar replacers (isomalt and lactitol) have been found to stimulate the growth of “good” bacteria in the intestine.

“The possibility of loose stools and gas can be reduced by eating only small quanitites of low-digestible carbohydrates. Give your body some time to adjust to digesting these foods.”

#buckroth, “My Diabetic Soul – An Autobiography, ISBN-13: 978-0-9822030-9-5 AND (ebook) – 10: 0-9822030-8; 304 pages references; > $15.95.

JDRF Advocacy

Honored to have been invited to speak at a monthly JDRF (Juvenile Diabetes Research Foundation) meeting, to share old and new information is exquisite, enlightening, encouraging!  Not all attendees were diabetic but attended in order to learn more about the increasing pandemic of T1D (Type One Diabetes).  That in itself is a wonderful acknowledgment.

Diagnosed in 1959 with this disease, my life is constructed, maneuvered and manipulated – by me – around and for my life with diabetes.  Oftentimes embarrassing and misunderstood, the JDRF organization is a welcome addition to positivity.  People know what I’m talking about; people want to learn and appreciate this incurable conundrum.

Having written and published four enlightening books on the subject, sales oftentimes exceed expectations.  I am delighted to share that many books were once again sold at and during this particular occasion.

My Diabetic Soul – An Autobiography is my first personal work of art.  It took me seven years to write it.  The title was specifically chosen due to my actually being able to relate and recognize that I do have a soul, a spirit, when I was six years old, attending the “Clara Barton Birthplace Camp” in North Oxford, Massachusetts, in 1964.  Nine consecutive summers of my childhood were spent there learning, sharing, experiencing, growing – with others – and this disease.  My Diabetic Soul – An Autobiography is a 304 page historically amazing account of life with this disease beginning in 1957; pictures inclusive; ISBN-13:978-0-9822030-9-5 and (e-book) -10: 0-9822030-9-8; $15.95; available at Amazon, CreateSpace, Smashwords, and libraries across the country; #buckroth..

Me & My Money…a child’s story of diabetes is a fictional account of a specific T1D, aged 8.  The story line goes that said child saves her allowance to adopt a puppy which then is also diagnosed with diabetes.  Another learning experience, this raises awareness of diabetes in animals.  Me & My Money…a child’s story of diabetes is a 104-page illustrated chapter book; ISBN-13:978-1490354873 and (e-book) -10: 1490354875; $14.00; easily available at Amazon, CreateSpace, Smashwords, and libraries across the country; #buckroth.

Me & My Money Too…a child’s story with diabetes is the second book in this series, also a fictional account of the same characters.  However, grave, life threatening circumstances are introduced due to one of many diabetes complications along with the introduction of a new character.  Also an illustrated chapter book, the ISBNs are -978-1500316327 and (e-book) -10:1500316326; $16.00; available at the same sources listed above.  View #buckroth for details.

Kisses for Cash Kali’s story…T1D meets T2D Book Three concludes the series, introducing new characters in the life of this T1D and her dog, Money.  One is a Grandmother, another is a dog, Cash!  A healthy lifestyle is encouraged for all members in and out of this family setting; it is another story-book of knowledge, happiness, and learning about daily functions with T1D and T2D (Type Two Diabetes).  Amazing if I may say so myself.  Kisses for Cash Kali’s story…T1D meets T2D Book Three is also an illustrated chapter book with 116 pages; ISBNs-13:978-1535349888 & (e-book) -10:1535349883; $18.00; easily available online and your local library(ies) by request.

These books were a great pleasure to write and illustrate – and re-read!  I know you will enjoy each and every one.

Thank you.

Andrea K. Roth (aka: A. K. Buckroth) #buckroth

“Action Words” to Assist Your Writing(s)!

Words.  As you know, words are used to communicate in a thousand different languages.  The English word list below has been re-typed to assist you in your word search.

As a long-time published author, I prefer to keep my characters active.  To me, action along with colorful descriptions for visualization and the use of all human senses, will engage any reader and  compliment your written – and even spoken works – especially if you’re creating a resume!

With that said, I hope this following alphabetized list will help you in your writing(s):

Accelerated     Adapted       Administered     Analyzed     Approved     Coordinated     Conceived     Conducted       Completed   Conducted         Completed   Controlled    Created            Delegated  Developed       Demonstrated       Directed    Effected       Eliminated   Evaluated         Expanded  Expected         Facilitated     Forwarded         Generated     Investigated   Influenced     Implemented  Instructed        Interpreted    Improved          Initiated        Launched     Led     Lectured   Maintained  Managed         Monitored     Motivated         Operated       Organized    Originated        Participated  Performed       Planned         Presented          Pinpointed     Prepared       Produced         Programmed  Proposed         Processed      Proved              Provided        Recommended    Reduced    Reinforced  Reorganized    Reported       Revamped        Revised          Reused          Scheduled        Set up  Solved             Sorted            Streamlined     Structured      Studied          Supervised       Supported  Surveyed         Taught           Wrote

Sure, there are more!  However, I have found these particular words to be especially helpful when writing a resume.  “A resume should verbally show you are a ‘doer.’  In describing your work experience and extracurricular activities, use words such as these to persuasively present your qualifications and background to prospective employers.”  Anonymous.

I hope you find the same and good luck in all your endeavors!

#buckroth

 

 

Diabetes Research “Updates From the Faustman Laboratory at Massachusetts General Hospital”

http://faustmanlab.org/docs/newsletters/DrFaustmanUpdate_Fall-2016.pdf

“Updates , Fall 2016.

“A Note from Dr. Faustman:
“Great things have happened this year! Most importantly, we began enrolling participants in our Phase II trial. This double-blind, randomized, placebo-controlled study in 150 participants will continue to investigate the ability of the BCG vaccine to reverse type 1 diabetes. Supported entirely by philanthropy, it is a clinical trial by the people, for the people.  With this trial, I hope that we will find a way to stop the body from destroying the insulin-producing cells of the pancreas and help the body restore blood sugars to normal levels.
“A decade ago, that may have seemed unachievable, but I believe it is a goal that we are coming closer to every day.  We are very proud to be doing this work and thank all who have helped us get here. We are touched by all of the individuals and families we hear from and see who are affected by type 1 diabetes, from the patients that donate blood for our research
to those who send in messages of support. The dedication and energy we are giving to this project is matched—if not exceeded—by the dedication and energy of our supporters.  Thank you all!
“On a more sober note, we are very deeply saddened each time we learn about a life lost to type 1 diabetes complications. As you read further, you will see that this is something we touch upon in one of the updates in this newsletter. The loss of life caused by this disease makes our research goals very real to us and very clear – we must find a way to stop type 1 diabetes.  I know that we all share this hope, and the Faustman Lab will continue to work towards this goal.
“Please contact us with any questions at diabetestrial@partners.org.
.
Thank you again!
Sincerely,
Denise L. Faustman, MD, PhD
“Long-Term Follow Up of the Phase I Trial Continues We continue to follow the progress of the patients who participated in the Phase I BCG study. All patients who were randomized to receive placebo during the blinded portion of the Phase I study have now received two doses of the BCG vaccine, just as the patients randomized to BCG did. We expect to publish data on our long-term follow up of all of the Phase I patients in 2017.
“Phase II Trial Updates…We now have over $20 million raised for the Phase II clinical trial.  The Phase II trial is a double-blind, randomized, placebo controlled study that will investigate the ability of the BCG vaccine to help those living with type 1 diabetes permanently lower their blood sugars. The primary endpoint of the trial will be to see if BCG helps to lower HbA1c.
 ‘To date, we have enrolled over 130 of the 150 candidates that we need for the trial, and have given at least one dose of the BCG vaccine or placebo to over 100 participants. We will follow participants over a five-year period. We will keep everyone updated with trial updates as they are available.
“$20 million raised BCG Trials in Multiple Sclerosis…Moving Forward in Italy…Our colleagues in Italy are moving forward with a Phase III trial testing BCG in patients with multiple sclerosis (MS). Led by Dr. Giovani Ristori at Sapienza University in Rome and supported by the Multiple Sclerosis Society of Europe, the trials will look at the clinical effect of BCG vaccinations in patients with early signs of MS. This is a follow up to their Phase II study, which showed that even a single dose of BCG stopped multiple sclerosis progression in over half of patients compared to placebo.
“www.faustmanlab.org
Faustman Immunobiology Lab Research Identifies & Corrects Regulatory T Cell (Treg) Defects in
Type 1 Diabetes. Regulatory T cells or “Tregs” are a type of white blood cell that helps regulate the immune system, and they normally should prevent autoimmune conditions like type 1 diabetes. In our latest type 1 diabetes research paper, we identified a defect in the Tregs of people with type 1 diabetes. Using human blood samples (thanks to everyone who donates blood for our research), we showed how tumor necrosis factor (TNF) is one way to correct this Treg defect.  Specifically, TNF treatment of type 1 diabetic Treg cells “awakens” the Tregs so that they become potent and functional again, fighting the cells that cause autoimmunity. Part of what we hope to do in our trials with the BCG vaccine (which is a known way to stimulate the body to produce
TNF) is to awaken these cells to put up a fight.  Our paper was published online in Nature Clinical & Translational Immunology in January this year.
“Kiss the Sky to Conquer Diabetes: A Tribute to Murphy (Murph) Roberts.  We featured the amazing efforts of Kiss the Sky to Conquer Diabetes (KTS) in our newsletter last year. For those who don’t know, KTS is a mountain climbing group led by Rick Noble. They joined the effort to help raise awareness for and finance our human clinical trials in 2004, and they have since taken
on some incredible climbing challenges in support of these goals.  This summer, KTS took on the
Six-Pack of Peaks Challenge, which Rick described as “6 peaks, 82 miles, over 27,000’ of vertical gain and one epic challenge to conquer diabetes!”  Right before setting out on the fifth and biggest climb of the challenge, the KTS team sadly learned of the passing of Murphy (Murph) Roberts, the brother of a friend of Rick’s daughter, Sarah.
“While hiking in Utah, Murph experienced a seizure related to his type 1 diabetes. The seizure caused a fall that resulted in a series of complications, leading to his death.  Murph, a member of the class of 2017 at Middlebury College in Vermont, is remembered as a great student and person, and an avid adventurer. He was also passionate about finding a cure for type 1 diabetes. As a tribute to Murph and with the blessing and support of Murph’s family, the KTS team has renewed their pledge to “keep climbing until we conquer type 1 diabetes.”
“Dr. Faustman and Charlotte, a young supporter whose very successful rollerskating fundraiser helped benefit the Faustman Lab’s research.”